BUSINESS● LOWSep 11 · Sep 11, 2026, 12:32 PM
Novo Nordisk falls as Morgan Stanley cuts rating to Underweight on semaglutide concern
Seeking Alpha Tech · global
Novo Nordisk's stock has declined following Morgan Stanley's downgrade of its rating to Underweight, citing concerns related to semaglutide. This reports on a significant development affecting a pharmaceutical company's market performance.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS41m agoBlue dollar today: at what price it is quoted this Sunday, November 1ClarínBUSINESS1h agoCompanies promised AI gains— here's how the payoff showed up in earningsCNBC